39
the nervous system: different roles, different sources and different
receptors. Neurochem Int 2001; 2: 107-125.
Dunwiddie T.V., Mansino S.A.. The role and regulation of adenosine in
central nervous system. Annu Rev Neursci 2001; 31-55.
Ferré S.. Adenosine-dopamine interactions in ventral striatum. Implications
for the tratament of schizophrenia. Psychopharmacology (Berl) 1997; 2:
107-20.
Franco R., Casadó V., Ciruela F., Saura C., Mallol J., Canela E., Lluis C..
Cell surface adenosine deaminase: much more than an ectoenzyme. Prog
Neurobiol 1997; 52: 283-94.
Fredholm B.B., Battig K., Holmen J., Nehlig A., Zvartau E.E.. Actions of
caffeine in the brain with special reference to factors that contribute to its
widespread use. Pharmacol Rev 1999; 1: 83-133.
Fredholm B.B., Chen J.F., Cunha R.A., Svenningsson P., Vaugeois J.M..
Adenosine and brain function. Int Rev Neurobiol 2005; 63: 191-279.
Ghisolfi E.S., Prokopiuk A.S., Becker J., Ehlers J.A., Belmont-de-Abreu P.,
Souza D.O. et al.. The adenosine antagonist theophyline impairs p50
auditory sensory gating in normal subjects. Neuropsychopharmacology
2002; 4: 629-37.
Hettinger J.A., Liu X., Jeltje J., Holden A.. The G22A polymorphism of the
ADA gene and susceptibility to autism spectrum disorders. J Autism Dev
Disord 2007; (38) 1: 14-19.
Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasma A., et al..
Coaggregation, cointernalization, and codesensitization of adenosine A2a
receptors and dopamine D2 receptors. J Biol Chem 2002; 20: 18091-7.
Hirschhorn R., Yang D.R., Israni A.. An Asp8Asn substitution results in the
adenosine deaminase (ADA) genetic polymorphism (ADA2 Allozyme):
occurrence on different chromosomal backgrounds and apparent intragenic
crossover. Ann Hum Genet 1994; 58: 1-9.
Kafka S.H., Cobertt R.. Selective adenosine A2a receptor/dopamine D2
receptor interactions in animal models of schizophrenia. Fur J Pharmacol
1996; 2-3: 147-54.
Keshavan M.S., Reynolds C.F. III, Miewald J.M. et al.. Delta sleep deficits in
schizophrenia. Arch Gen Psychiatry 1998; 55: 443-448.
Krystal J.H., Anand A., Moghaddam B.. Effects of NMDA receptor
antagonists: implications for the pathophysiology of schizophrenia. Arch
Gen Psychiatry 2002; 7: 663-4.
Lara D.R., Souza D.O.. Schizophrenia: a purinergic hypothesis. Medical
hypothesis, 54 (2), 157-166, 2000.
Lara D.R., Dall’Igna O.P., Ghisolfi E.S., Brunstein M.G.. Involvement of
adenosine in the neurobiology of schizophrenia and its therapeutic
implications. Prog Neuro-Psych Biol Psych 2006, 30: 617-29.
Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M.,
Vanderhaeghen J.J., et al.. Aggressiveness, hypoalgesia and high blood
pressure in mice lacking the adenosine A2a receptor. Nature 1997; 6643:
674-8.
Mills G.C., Schmaltieg F.C., Trimmer K.B., Goldman A.S., Goldblum R.M..
Purine metabolism in adenosine deaminase deficiency. Proc natn Acad Sci
U.S.A. 1976; 2867-2871.
Nishino S., Mognot E., Benson K.L., Zarcone V.P.Jr.. Cerebrospinal fluid
prostaglandins and corticotropin resealing factor in schizophrenics and